Katelyn T. Byrne

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Divij Mathew, Josephine R. Giles, Amy E. Baxter et al. · Science · 2020 · 1.7K citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Jinyang Li, Katelyn T. Byrne, Fangxue Yan et al. · Immunity · 2018 · 757 citations · Full text

Medicine, Immunology, Oncology +14

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

Rafael Winograd, Katelyn T. Byrne, Rebecca A. Evans et al. · Cancer Immunology Research · 2015 · 468 citations · Full text

Life Sciences, Immunology, Oncology +17

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 350 citations · Full text

Medicine, Oncology, Pharmacology +15

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary et al. · The Lancet Oncology · 2020 · 301 citations

Medicine, Oncology, Pharmacology +15